- Approval of an India-made generic version of the long-acting HIV-prevention shot (lenacapavir) offers hope for affordable access in low-income countries. - India's generic pharmaceutical industry plays a critical role in global health equity by producing affordable life-saving therapeutics. - Access to high-cost advanced drugs remains hindered by intellectual property rights and patent monopolies unless voluntary licensing or patent pool agreements are facilitated. - Affordability and scale-up are vital for achieving the global public health goal of ending HIV/AIDS as a public health threat by 2030. - **TRIPS Agreement:** An international legal agreement administered by the WTO that sets minimum standards for the protection and enforcement of intellectual property rights, impacting global access to affordable generic medicines. - **World Health Organization:** A United Nations specialized agency responsible for international public health, setting normative guidelines, pre-qualifying essential medicines, and coordinating global responses to epidemics like HIV/AIDS. - **Medicines Patent Pool:** A United Nations-backed public health organization that works to facilitate the development, manufacturing, and generic licensing of life-saving medicines for low- and middle-income countries. **Introduction** The approval of an India-manufactured generic version of a critical long-acting HIV-prevention injection has raised optimism for expanding affordable healthcare access across low-income nations. This development highlights India's pivotal position as the 'pharmacy of the developing world', lowering costs for life-saving pharmaceuticals through robust generic manufacturing capacities while underscoring ongoing debates surrounding global intellectual property rights and public health equity. **Core Issue and Detailed Points** - Approval of an India-made generic version of the long-acting HIV-prevention shot (lenacapavir) offers hope for affordable access in low-income countries. - India's generic pharmaceutical industry plays a critical role in global health equity by producing affordable life-saving therapeutics. - Access to high-cost advanced drugs remains hindered by intellectual property rights and patent monopolies unless voluntary licensing or patent pool agreements are facilitated. - Affordability and scale-up are vital for achieving the global public health goal of ending HIV/AIDS as a public health threat by 2030. **Key Statutory Bodies, Acts & Concepts** - **TRIPS Agreement:** An international legal agreement administered by the WTO that sets minimum standards for the protection and enforcement of intellectual property rights, impacting global access to affordable generic medicines. - **World Health Organization:** A United Nations specialized agency responsible for international public health, setting normative guidelines, pre-qualifying essential medicines, and coordinating global responses to epidemics like HIV/AIDS. - **Medicines Patent Pool:** A United Nations-backed public health organization that works to facilitate the development, manufacturing, and generic licensing of life-saving medicines for low- and middle-income countries.